This trial is testing a new RSV vaccine to see if it is safe and effective.
- Respiratory Syncytial Virus
6 Primary · 9 Secondary · Reporting Duration: Baseline and 1, 6, 12, 18, and 24 months postinjection
2 Treatment Groups
1 of 2
1 of 2
37000 Total Participants · 2 Treatment Groups
Primary Treatment: mRNA-1345 · Has Placebo Group · Phase 2 & 3
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
|District of Columbia||17.6%|
How old are they?
|18 - 65||50.0%|
What site did they apply to?
|Velocity Clinical Research, San Diego||4.2%|
|Meridian Clinical Research- Rockville, MD||4.2%|
|Washington Health Institute||79.2%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||87.9%|
Why did patients apply to this trial?
- "I don't have"
- "Am new to the program"
- "I wish to advance medical science."
- "I am interested in doing any clinical trials I qualify for. I have participated in clinical trials before with PMG. I live in Wilmington"
How many prior treatments have patients received?
Frequently Asked Questions
Are there a significant number of hospitals participating in this trial within the state?
"74 patients are enrolled in this study with locations at the Washington Health Institute, Velocity Clinical Research, Valparaiso, Meridian Clinical Research, as well as 74 other sites." - Anonymous Online Contributor
Are we able to include new patients in this research project?
"This trial, which was first advertised on November 17th 2021, is still looking for participants. The December 23rd 2021 edit to the listing on clinicaltrials.gov was likely a typos." - Anonymous Online Contributor